Abstract：
UNASSIGNED: Stimulator of Interferon Genes (STING) is an innate immune sensor. Activation of STING triggers a downstream response that results in the expression of proinflammatory cytokines (TNF-α, IL-1β) via nuclear factor kappa-B (NF-κB) or the expression of type I interferons (IFNs) via an interferon regulatory factor 3 (IRF3). IFNs can eventually result in promotion of the adaptive immune response including activation of tumor-specific CD8+ T cells to abolish the tumor. Consequently, activation of STING has been considered as a potential strategy for cancer treatment.
UNASSIGNED: This article provides an overview on structures and pharmacological data of CDN-like and non-nucleotide STING agonists acting as anticancer agents (January 2021 to October 2023) from a medicinal chemistry perspective. The data in this review come from EPO, WIPO, RCSB PDB, CDDI.
UNASSIGNED: In recent years, several structurally diverse STING agonists have been identified. As an immune enhancer, they are used in the treatment of tumors, which has received extensive attention from scientific community and pharmaceutical companies. Despite the multiple challenges that have appeared, STING agonists may offer opportunities for immunotherapy.
UNASSIGNED: This article provides an overview on structures and pharmacological data of CDN-like and non-nucleotide STING agonists acting as anticancer agents (January 2021 to October 2023) from a medicinal chemistry perspective. The data in this review come from EPO, WIPO, RCSB PDB, CDDI.
UNASSIGNED: In recent years, several structurally diverse STING agonists have been identified. As an immune enhancer, they are used in the treatment of tumors, which has received extensive attention from scientific community and pharmaceutical companies. Despite the multiple challenges that have appeared, STING agonists may offer opportunities for immunotherapy.
摘要：
■干扰素基因刺激因子（STING）是一种先天性免疫传感器。STING的激活引发下游反应，导致促炎细胞因子（TNF-α，IL-1β）通过核因子κB（NF-κB）或通过干扰素调节因子3（IRF3）表达I型干扰素（IFN）。IFN最终可以导致适应性免疫应答的促进,包括激活肿瘤特异性CD8+T细胞以消除肿瘤。因此,STING的激活已被认为是癌症治疗的潜在策略。
■本文从药物化学角度概述了充当抗癌剂的CDN样和非核苷酸STING激动剂（2021年1月至2023年10月）的结构和药理数据。本评论中的数据来自EPO，WIPO,RCSBPDB,CDDI。
■近年来，已经鉴定了几种结构不同的STING激动剂。作为免疫增强剂,它们用于治疗肿瘤，受到科学界和制药公司的广泛关注。尽管出现了多重挑战，STING激动剂可能为免疫治疗提供机会。
■本文从药物化学角度概述了充当抗癌剂的CDN样和非核苷酸STING激动剂（2021年1月至2023年10月）的结构和药理数据。本评论中的数据来自EPO，WIPO,RCSBPDB,CDDI。
■近年来，已经鉴定了几种结构不同的STING激动剂。作为免疫增强剂,它们用于治疗肿瘤，受到科学界和制药公司的广泛关注。尽管出现了多重挑战，STING激动剂可能为免疫治疗提供机会。
